THX Pharma Société Anonyme (EPA:ALTHX)

France · Delayed Price · Currency is EUR

3.160

-0.240 (-7.06%)

Oct 2, 2026, 5:35 PM CET

Market Cap	46.91M +86.1%
Revenue (ttm)	806.05K -64.7%
Net Income	-3.00M
EPS	-0.22
Shares Out	13.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	146,959
Open	3.320
Previous Close	3.400
Day's Range	3.060 - 3.320
52-Week Range	1.490 - 5.100
Beta	1.51
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 12

Stock Exchange Euronext Paris

Ticker Symbol ALTHX

Full Company Profile

Financial Performance

In 2025, EPA:ALTHX's revenue was 806,045, a decrease of -64.70% compared to the previous year's 2.28 million. Losses were -3.00 million, 70.0% more than in 2024.

Financial Statements